Event Abstract

The extended phenotype of LRBA deficiency

  • 1 University Medical Center Freiburg, Center for Chronic Immunodeficiency, Germany
  • 2 Hadassah Hebrew University Hospital, Pediatric Hematology-Oncology and Bone Marrow Transplantation, Israel
  • 3 Medical University Graz, Deparment of Pediatrics and Adolescent Medicine, Divisioni of Pediatric Hematology-Oncology, Austria
  • 4 Medical and Dental University, Tokyo, Japan, Department of Pediatrics and Developmental Biology Graduate School of Medical and Dental Sciences, Japan
  • 5 Great Ormond Street Hospital for Children, Department of Immunology, United Kingdom
  • 6 Cincinnati Childrens Hospital Medical Center, University of Cincinnati Medical School, United States
  • 7 Radboud University of Cincinnati Medical School, Cincinnati Childrens Hospital Medical Center, Netherlands
  • 8 University Hospital Tübingen, laboratory of Immunotherapy, Germany
  • 9 Aghia Sophia Childrens Hospital, Department of Immunology, Greece
  • 10 Royal Free Hospital Foundation Trust, UCL Center for Immunodeficiency, United Kingdom
  • 11 University Childrens Hospital Munich, Division of Immunology and Infectious Disease, Germany
  • 12 Tehran University of Medical Sciences, Research Center for Immunodeficiencies, Iran
  • 13 Goethe University Frankfurt am Main, Division for Stem Cell Transplantation and Immunology, Germany

Background: LRBA (lipopolysaccharide-responsive-beige-like-anchor-protein) deficiency is a primary immunodeficiency caused by biallelic mutations in LRBA that abolish LRBA protein expression. Objective: We sought to report the extended phenotype of LRBA deficiency in a cohort of 22 LRBA-deficient patients. Methods: Clinical criteria, protein detection, and genetic sequencing were applied to diagnose LRBA deficiency. Results: Ninety-three patients met the inclusion criteria, and were considered “possible” LRBA deficiency. Twenty-four patients failed to express LRBA protein and were labeled “probable” LRBA deficiency whereas 22 were genetically confirmed as “definitive” LRBA deficiency, having biallelic mutations in LRBA. Seventeen of these were novel and included homozygous or compound heterozygous mutations. Immune dysregulation (95%), organomegaly (86%), recurrent infections (71%), and hypogammaglobulinemia (57%) were the main clinical complications observed in LRBA-deficient patients. Although 81% of LRBA-deficient patients had normal T cell counts, 73% had reduced regulatory T cell numbers. Most LRBA-deficient patients had low counts in the B cell subsets mainly in switched memory B cells (80%) and plasmablasts (92%) with a defective specific antibody response in 67%. Out of the 22 patients, three were deceased, two had successfully been treated by HSCT, seven patients are under immunoglobulin replacement, and 15 are on immunosuppressive treatment with systemic corticosteroids, alone or in combination with steroids sparing agents. Conclusion: This report describes the largest cohort of patients with LRBA deficiency and offers guidelines for physicians to identify LRBA deficiency, supporting an appropriate clinical management.


This study was supported by the Bundesministerium für Bildung und Forschung (BMBF) grant numbers: IFB/CCI: 01E01303, E-med SysINFLAME: 012X1306F, DZIF: 8000805-3, and BMBF PID-NET:01GM1111B.


1. Al-Herz W, Bousfiha A, Casanova JL, Chatila T, Conley ME, Cunningham-Rundles C, et al. Primary immunodeficiency diseases: an update on the classification from the international union of immunological societies expert committee for primary immunodeficiency. Frontiers in immunology. 2014;5:162.
2. Lopez-Herrera G, Tampella G, Pan-Hammarstrom Q, Herholz P, Trujillo-Vargas CM, Phadwal K, et al. Deleterious mutations in LRBA are associated with a syndrome of immune deficiency and autoimmunity. American journal of human genetics. 2012;90(6):986-1001.
3. Alangari A, Alsultan A, Adly N, Massaad MJ, Kiani IS, Aljebreen A, et al. LPS-responsive beige-like anchor (LRBA) gene mutation in a family with inflammatory bowel disease and combined immunodeficiency. The Journal of allergy and clinical immunology. 2012;130(2):481-8 e2.
4. Serwas NK, Kansu A, Santos-Valente E, Kuloglu Z, Demir A, Yaman A, et al. Atypical manifestation of LRBA deficiency with predominant IBD-like phenotype. Inflammatory bowel diseases. 2015;21(1):40-7.
5. Burns SO, Zenner HL, Plagnol V, Curtis J, Mok K, Eisenhut M, et al. LRBA gene deletion in a patient presenting with autoimmunity without hypogammaglobulinemia. The Journal of allergy and clinical immunology. 2012;130(6):1428-32.
6. Charbonnier LM, Janssen E, Chou J, Ohsumi TK, Keles S, Hsu JT, et al. Regulatory T-cell deficiency and immune dysregulation, polyendocrinopathy, enteropathy, X-linked-like disorder caused by loss-of-function mutations in LRBA. The Journal of allergy and clinical immunology. 2015;135(1):217-27 e9.
7. Cullinane AR, Schaffer AA, Huizing M. The BEACH is hot: a LYST of emerging roles for BEACH-domain containing proteins in human disease. Traffic. 2013;14(7):749-66.
8. Wang JW, Howson J, Haller E, Kerr WG. Identification of a novel lipopolysaccharide-inducible gene with key features of both A kinase anchor proteins and chs1/beige proteins. Journal of immunology. 2001;166(7):4586-95.
9. Wang JW, Gamsby JJ, Highfill SL, Mora LB, Bloom GC, Yeatman TJ, et al. Deregulated expression of LRBA facilitates cancer cell growth. Oncogene. 2004;23(23):4089-97.
10. Turner D, Travis SP, Griffiths AM, Ruemmele FM, Levine A, Benchimol EI, et al. Consensus for managing acute severe ulcerative colitis in children: a systematic review and joint statement from ECCO, ESPGHAN, and the Porto IBD Working Group of ESPGHAN. The American journal of gastroenterology. 2011;106(4):574-88.
11. Seidel MG, Hirschmugl T, Gamez-Diaz L, Schwinger W, Serwas N, Deutschmann A, et al. Long-term remission after allogeneic hematopoietic stem cell transplantation in LPS-responsive beige-like anchor (LRBA) deficiency. The Journal of allergy and clinical immunology. 2014.
12. Park JH, Levinson AI. Granulomatous-lymphocytic interstitial lung disease (GLILD) in common variable immunodeficiency (CVID). Clinical immunology. 2010;134(2):97-103.
13. Yong PF, Thaventhiran JE, Grimbacher B. "A rose is a rose is a rose," but CVID is Not CVID common variable immune deficiency (CVID), what do we know in 2011? Advances in immunology. 2011;111:47-107.
14. Revel-Vilk S, Fischer U, Keller B, Nabhani S, Gamez-Diaz L, Rensing-Ehl A, et al. Autoimmune lymphoproliferative syndrome-like disease in patients with LRBA mutation. Clinical immunology. 2015.
15. Beck C, Morbach H, Beer M, Stenzel M, Tappe D, Gattenlohner S, et al. Chronic nonbacterial osteomyelitis in childhood: prospective follow-up during the first year of anti-inflammatory treatment. Arthritis research & therapy. 2010;12(2):R74.
16. Comans-Bitter WM, de Groot R, van den Beemd R, Neijens HJ, Hop WC, Groeneveld K, et al. Immunophenotyping of blood lymphocytes in childhood. Reference values for lymphocyte subpopulations. The Journal of pediatrics. 1997;130(3):388-93.

Keywords: LRBA, Primary immunodeficiency, CVID, Autoimmunity, hypogammaglobulinemia, enteropathy, LYMPHOPROLIFERATION

Conference: IMMUNOCOLOMBIA2015 - 11th Congress of the Latin American Association of Immunology - 10o. Congreso de la Asociación Colombiana de Alergia, Asma e Inmunología, Medellin, Colombia, 13 Oct - 16 Oct, 2015.

Presentation Type: Oral Presentation

Topic: Immunodeficiencies

Citation: Gámez-Díaz L, August D, Stepensky P, Revel-Vilk S, Seidel MG, Noriko M, Morio T, Worth A, Bleesing J, Van De Veerdonk F, Feuchtinger T, Kanariou MG, Schmitt-Gräff A, Seneviratne S, Burns S, Belohradsky B, Rezaei N, Bakhtiar S, Speckmann C, Jordan M and Grimbacher B (2015). The extended phenotype of LRBA deficiency. Front. Immunol. Conference Abstract: IMMUNOCOLOMBIA2015 - 11th Congress of the Latin American Association of Immunology - 10o. Congreso de la Asociación Colombiana de Alergia, Asma e Inmunología. doi: 10.3389/conf.fimmu.2015.05.00351

Copyright: The abstracts in this collection have not been subject to any Frontiers peer review or checks, and are not endorsed by Frontiers. They are made available through the Frontiers publishing platform as a service to conference organizers and presenters.

The copyright in the individual abstracts is owned by the author of each abstract or his/her employer unless otherwise stated.

Each abstract, as well as the collection of abstracts, are published under a Creative Commons CC-BY 4.0 (attribution) licence (https://creativecommons.org/licenses/by/4.0/) and may thus be reproduced, translated, adapted and be the subject of derivative works provided the authors and Frontiers are attributed.

For Frontiers’ terms and conditions please see https://www.frontiersin.org/legal/terms-and-conditions.

Received: 28 May 2015; Published Online: 15 Sep 2015.

* Correspondence: Miss. Laura Gámez-Díaz, University Medical Center Freiburg, Center for Chronic Immunodeficiency, Freiburg, Select State, 79108, Germany, laura.gamez@uniklinik-freiburg.de